GMP Expectations for Products Used in Early Phase IND Studies

Posted By : User Ref No: WURUR54291 0
  • Image
  • TypeWebinar
  • Image
  • Location Fremont, California, United States
  • Price
  • Date 23-04-2020
GMP Expectations for Products Used in Early Phase IND Studies, Fremont, California, United States
Webinar Title
GMP Expectations for Products Used in Early Phase IND Studies
Event Type
Webinar
Webinar Date
23-04-2020
Last Date for Applying
22-04-2020
Location
Fremont, California, United States
Organization Name / Organize By
Compliance4all
Organizing/Related Departments
Online Training
Organization Type
Organization/Company
WebinarCategory
Both (Technical & Non Technical)
WebinarLevel
All (State/Province/Region, National & International)
Related Industries

Education/Teaching/Training/Development

Business Development

Administration/Management

Manufacturing

Medical/Healthcare/Hospital

Location
Fremont, California, United States

Overview:

FDA issued a guidance document covering GMP requirements for Phase 1 products.

These guidelines remove some of the problems that are encountered with early phase products and are in addition to those that cover the CMC sections for IND submissions at Phase 1.

Although the guidance appears to remove the need to follow GMPs for Phase 1 products, the need to follow GMPs is still present in the Food, Drug, and Cosmetic Act. Thus the nature and extent of GMP-related activities will depend upon the nature of the investigational drug and the extent of the study that is planned.

Areas Covered in the Session:

  • Discussion of the elements found in the guidance document for Phase 1 material
  • What to do at really early stages
  • What about special IND studies?
  • What about preclinical studies?
  • Varying GMP activities that depend upon the nature of the IND product
  • What are the requirements for the GMP found in the Food, Drug, and Cosmetic Act?
  • What to do about QC activities such as instrument qualification, method validation, and process validation


Who Will Benefit:

  • Regulatory Affairs Personnel who Coordinate Activities for the CMC Sections of Submissions
  • QA/QC Personnel who Need to Plan Work on Early Stage Material
  • R & D Personnel who Will Contribute data to CMC Sections
  • Project Managers for Product Development Studies
  • Quality Systems Auditors
  • Consultants

 

 

Speaker Profile

Steven S. Kuwahara , Ph.D. is the founder and Principal of GXP BioTechnology LLC, a consulting firm that works in the areas covered by the GLP and GMP of drugs, biologics, and nutraceuticals. Steven has over 30 years of experience in supervising quality control laboratories, including an animal testing facility, and in performing GLP and GMP audits of internal and external testing laboratories . Steven has participated in the development of drugs and biologicals through all phases of clinical research and final product production.

Event link:

https://www.compliance4all.com/webinar/-502958LIVE?channel=eventsget_2020_SEO

Contact Info

Netzealous LLC, DBA -Compliance4all

Email: [email protected]

Phone: +1-800-447-9407

Website: https://www.compliance4all.com/

 

Others Details

Contact Info Netzealous LLC, DBA -Compliance4all Email: [email protected] Phone: +1-800-447-9407 Website: https://www.compliance4all.com/

Registration Fees
Available
Registration Fees Details
$150
Registration Ways
Website
Address/Venue
  Online  Pin/Zip Code : 94539
Landmark
California
Official Email ID
Contact
Netzealous LLC,DBA -Compliance4all

39658 Mission Boulevard, Fremont, CA 94539, USA.

[email protected]

   8004479407    Fax No: 94539